• For Institutions

    • Corporate Services
    • Developers
  • Download
  • Help
  • About

    • Company Profile
    • License & Regulatory
    • Media coverage
longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Dec8
Syndax Pharmaceuticals Announces Positive Trial Results for Revuforj® in AML at ASH Annual Meeting
11:50
Nov24
Barclays Maintains Overweight Rating and Raises Target Price for Syndax Pharmaceuticals
18:57
Nov14
H.C. Wainwright and J.P. Morgan Reiterate Buy Rating on Syndax Pharmaceuticals
11:42
Nov4
Syndax Pharmaceuticals Reports Exceeding EPS Expectations for Q3, Stock Price Rises
17:23
Lawson Reiterates Buy Rating on Syndax Pharmaceuticals
07:56
Syndax Pharma released FY2025 9 Months Earnings on November 3 After-Market EST, with actual revenue of USD 58 M and EPS of USD -1.8167
00:00

Schedules & Filings

Schedules
Filings
Nov3
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 45.87 M, Net Income -60.72 M, EPS -0.7009

Aug4
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 37.96 M, Net Income -71.85 M, EPS -0.8321

May5
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 20.04 M, Net Income -84.85 M, EPS -0.9846

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
EKSO
10.580
+93.77%
+5.120
AEHL
2.180
+92.92%
+1.050
AFJK
82.580
+89.19%
+38.930
PFSA
0.1218
+78.33%
+0.053
DLXY
1.410
+67.86%
+0.570
ULY
2.760
+52.49%
+0.950
MENS
4.220
+51.80%
+1.440
CETX
2.980
+41.23%
+0.870
DAIC
0.5500
+39.06%
+0.154
ONTF
8.060
+37.54%
+2.200
View More